Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

QUOTES-U.S. backs giving poorer countries access to COVID-19 vaccine patents, reversing stance

Thu, 06th May 2021 10:30

(Adds material)

May 6 (Reuters) - U.S. President Joe Biden on Wednesday
supported waiving intellectual property rights for COVID-19
vaccines, bowing to mounting pressure from Democratic lawmakers
and more than 100 other countries, but angering pharmaceutical
companies.

Following are reactions to the latest developments.

GAVI, THE GLOBAL VACCINE ALLIANCE

"We recognise also the significance of the (Biden)
administration’s commitment to work towards increasing raw
material production which will have an immediate impact on
alleviating current global supply constraints.

"Gavi urges now that in the interests of global equitable
access the US supports manufacturers to transfer not only IP but
also know-how in a bid to urgently boost global production."

THE INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS
& ASSOCIATIONS (IFPMA)

"Waiving patents of COVID-19 vaccines will not increase
production nor provide practical solutions needed to battle this
global health crisis. On the contrary, it is likely to lead to
disruption.

"The only way to ensure quick scaling up of and equitable
vaccine access to all those in need remains pragmatic and
constructive dialogue with the private sector."

SOUTH AFRICAN GOVERNMENT

"President (Cyril) Ramaphosa welcomes the position adopted
by the United States as an important reinforcement of a campaign
led by South Africa and India on behalf of emerging economies
that face vaccine shortages and production challenges.

"The anticipated temporary waiver provides a global response
to COVID-19. The proposal establishes a global solution to
enhance manufacturing and boost supply capacity, and enables
coordination and access to information currently under patent
protection.

"For countries that do not currently have manufacturing
capacity on certain medical technologies, the waiver could open
up more supply options and avoid countries being reliant on only
one or two suppliers. Where supply capacity currently exists, it
can be repurposed to COVID vaccine production and in this way
improve the supply available to all nations."

AUSTRALIAN TRADE MINISTER DAN TEHAN

"We welcome this positive development and look forward to
working with the U.S. and others to find solutions that boost
the global rollout of COVID-19 vaccines.

"Close collaboration between governments and vaccine
manufacturers will remain vital."

NEW ZEALAND TRADE MINISTER DAMIEN O'CONNOR

"New Zealand supports the waiver of IP protections on
vaccines as an important part of our collective efforts to
address the human catastrophe of the pandemic.

"We are also working in APEC, the WTO and other fora to
address other elements of vaccine supply issues including
through the supply chains that are limiting the availability of
vaccines regionally and globally."

ITALIAN MINISTRY OF HEALTH ROBERTO SPERANZA

"Biden's breakthrough on free access to vaccine patents for
all is an important step forward. Europe must also play its
part. This pandemic has taught us that we can only win
together."

DOCTORS WITHOUT BORDERS

"It is crucial that the waiver not just apply to
preventative vaccines, but it should also cover other medical
tools for COVID-19, including treatments for people who fall ill
and diagnostics to help curb the spread, as originally proposed
seven months ago.

"While this decision means other manufacturers will have the
information they need from pharmaceutical corporations - and the
legal permission - to help scale up global supply and get more
shots into the arms of people everywhere, this won't happen
immediately.

"For the remaining countries that continue to oppose the WTO
waiver..., they must drop their objections and put people’s
health before pharmaceutical profits, and waive IP on all
COVID-19 medical tools, including vaccines."

OXFAM HEALTH POLICY MANAGER ANNA MARRIOTT

“In this moment of crisis, we applaud the decision of
President Biden and his administration to pursue a new path that
prioritizes public health over private profits.

"This is a testament to the widespread public movement
calling for an end to vaccine monopolies.

“We are at a crucial point in the fight against coronavirus,
yet we have remained essentially at the mercy of a handful of
giant pharmaceutical corporations that have monopoly control
over the life-saving technologies we all need. The UK shouldn't
be left standing on the wrong side of history and must join the
U.S. in doing the right thing for humanity.

“We will now look to the White House for leadership in a
strong WTO outcome, in urgently insisting on the transfer of
technologies through the World Health Organization COVID-19
Technology Access pool, and in investing strategically to build
up regional vaccine hubs to defeat this and future pandemics."

GORDON BROWN, U.N. GLOBAL AMBASSADOR AND FORMER BRITISH
PRIME MINISTER

"I welcome the American decision on temporary patent waiver
which makes the COVID-19 vaccine accessible. Now we must make
the vaccine affordable. No one is safe until everyone is safe
and on June 11, at the G7 meeting, the richest countries should
make the momentous decision to pay two thirds of the $60 billion
cost of vaccinating the world."
(Reporting by Reuters staff; Editing by Nick Macfie and Mark
Heinrich)

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.